NRNP 6552 WOMEN’S HEALTH
2024 | Original Graduate Nursing Practice Exam
100 Multiple-Choice Questions with Answers and Rationales
Independent practice material — not an actual Walden University course exam.
Questions are original and are not copied from a live exam, proprietary test bank, or university
assessment. This document is not Walden University-endorsed, professor-verified, or a
representation of the NRNP 6552 final-exam blueprint. It is a study resource broadly organized
around the women’s health and primary-care topics listed in the request and advanced-practice
nursing concepts.
Educational use only. Clinical guidelines and laws may vary or change; confirm current local
guidance, prescribing information, scope-of-practice rules, and jurisdiction-specific consent and
reporting requirements before applying information in practice.
Reference basis includes 2024 USPSTF breast-screening and CDC U.S. Medical Eligibility
Criteria guidance, CDC STI treatment recommendations, ACOG patient and practice guidance,
and other standard women’s health references.
Page 1 of 37
,Table of Contents
Section 1: Women’s Health Assessment, Screening & Preventive Care (Questions 1–15)
...................................... 3
Section 2: Reproductive Anatomy, Physiology & Menstrual Disorders (Questions 16–30)
...................................... 8
Section 3: Contraception, Family Planning & Sexual Health (Questions 31–45)
...................................... 13
Section 4: Pregnancy, Prenatal Care & Postpartum Management (Questions 46–60)
...................................... 18
Section 5: Gynecologic Infections, Disorders & Oncology (Questions 61–75) ......................................
23
Section 6: Menopause, Hormone Therapy & Aging Women’s Health (Questions 76–90)
...................................... 29
Section 7: Psychosocial, Ethical & Interprofessional Women’s Health Practice (Questions 91–100)
...................................... 34
Page 2 of 37
,Section 1: Women’s Health Assessment, Screening & Preventive Care
(Questions 1–15)
Q1: Which recommendation is appropriate for average-risk breast cancer screening?
A. Recommend screening mammography every 2 years through age 74, with individualized care
if her risk or health status changes [CORRECT]
B. Recommend annual mammography for every patient regardless of risk
C. Defer screening until a breast lump develops
D. Order screening MRI instead of mammography for all average-risk patients
Correct Answer: A
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk call for a separate diagnostic and
risk-based plan. The other options are less appropriate, unsafe, or inconsistent with the clinical
priority.
Q2: Which clinical principle should guide care for average-risk breast cancer screening?
A. Defer screening until a breast lump develops
B. Order screening MRI instead of mammography for all average-risk patients
C. Stop screening at age 50
D. Recommend screening mammography every 2 years through age 74, with individualized care
if her risk or health status changes [CORRECT]
Correct Answer: D
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk call for a separate diagnostic and
risk-based plan. The other options are less appropriate, unsafe, or inconsistent with the clinical
priority.
Q3: Situation: a healthy 52-year-old with no breast symptoms, prior breast cancer, or
high-risk mutation asks when her next screening mammogram is due. For average-risk
breast cancer screening, which evidence-based principle applies?
A. Recommend screening mammography every 2 years through age 74, with individualized care
if her risk or health status changes [CORRECT]
B. Order screening MRI instead of mammography for all average-risk patients
C. Recommend annual mammography for every patient regardless of risk
D. Stop screening at age 50
Correct Answer: A
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk call for a separate diagnostic and
risk-based plan. The other options are less appropriate, unsafe, or inconsistent with the clinical
priority.
Page 3 of 37
, Q4: A patient presents with the following history: a healthy 52-year-old with no breast
symptoms, prior breast cancer, or high-risk mutation asks when her next screening
mammogram is due. Which action is most appropriate?
A. Defer screening until a breast lump develops
B. Recommend annual mammography for every patient regardless of risk
C. Stop screening at age 50
D. Recommend screening mammography every 2 years through age 74, with individualized care
if her risk or health status changes [CORRECT]
Correct Answer: D
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk call for a separate diagnostic and
risk-based plan. The other options are less appropriate, unsafe, or inconsistent with the clinical
priority.
Q5: Priority situation: a healthy 52-year-old with no breast symptoms, prior breast cancer,
or high-risk mutation asks when her next screening mammogram is due. Which action
addresses the highest-risk issue?
A. Recommend annual mammography for every patient regardless of risk
B. Recommend screening mammography every 2 years through age 74, with individualized care
if her risk or health status changes [CORRECT]
C. Order screening MRI instead of mammography for all average-risk patients
D. Defer screening until a breast lump develops
Correct Answer: B
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk call for a separate diagnostic and
risk-based plan. The other options are less appropriate, unsafe, or inconsistent with the clinical
priority.
Q6: Which recommendation is appropriate for cervical cancer screening interval?
A. Perform cervical screening at every visit regardless of the last result
B. Order HPV cotesting every year for all patients under 30
C. Stop screening because she received HPV vaccination
D. Explain that routine cytology is due at a 3-year interval for average-risk patients ages 21–29,
so she is not yet due [CORRECT]
Correct Answer: D
Rationale: For average-risk patients ages 21–29, the 2018 USPSTF guidance in effect in
2024 recommends cytology every 3 years; vaccination does not eliminate routine screening.
The other options are less appropriate, unsafe, or inconsistent with the clinical priority.
Page 4 of 37
2024 | Original Graduate Nursing Practice Exam
100 Multiple-Choice Questions with Answers and Rationales
Independent practice material — not an actual Walden University course exam.
Questions are original and are not copied from a live exam, proprietary test bank, or university
assessment. This document is not Walden University-endorsed, professor-verified, or a
representation of the NRNP 6552 final-exam blueprint. It is a study resource broadly organized
around the women’s health and primary-care topics listed in the request and advanced-practice
nursing concepts.
Educational use only. Clinical guidelines and laws may vary or change; confirm current local
guidance, prescribing information, scope-of-practice rules, and jurisdiction-specific consent and
reporting requirements before applying information in practice.
Reference basis includes 2024 USPSTF breast-screening and CDC U.S. Medical Eligibility
Criteria guidance, CDC STI treatment recommendations, ACOG patient and practice guidance,
and other standard women’s health references.
Page 1 of 37
,Table of Contents
Section 1: Women’s Health Assessment, Screening & Preventive Care (Questions 1–15)
...................................... 3
Section 2: Reproductive Anatomy, Physiology & Menstrual Disorders (Questions 16–30)
...................................... 8
Section 3: Contraception, Family Planning & Sexual Health (Questions 31–45)
...................................... 13
Section 4: Pregnancy, Prenatal Care & Postpartum Management (Questions 46–60)
...................................... 18
Section 5: Gynecologic Infections, Disorders & Oncology (Questions 61–75) ......................................
23
Section 6: Menopause, Hormone Therapy & Aging Women’s Health (Questions 76–90)
...................................... 29
Section 7: Psychosocial, Ethical & Interprofessional Women’s Health Practice (Questions 91–100)
...................................... 34
Page 2 of 37
,Section 1: Women’s Health Assessment, Screening & Preventive Care
(Questions 1–15)
Q1: Which recommendation is appropriate for average-risk breast cancer screening?
A. Recommend screening mammography every 2 years through age 74, with individualized care
if her risk or health status changes [CORRECT]
B. Recommend annual mammography for every patient regardless of risk
C. Defer screening until a breast lump develops
D. Order screening MRI instead of mammography for all average-risk patients
Correct Answer: A
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk call for a separate diagnostic and
risk-based plan. The other options are less appropriate, unsafe, or inconsistent with the clinical
priority.
Q2: Which clinical principle should guide care for average-risk breast cancer screening?
A. Defer screening until a breast lump develops
B. Order screening MRI instead of mammography for all average-risk patients
C. Stop screening at age 50
D. Recommend screening mammography every 2 years through age 74, with individualized care
if her risk or health status changes [CORRECT]
Correct Answer: D
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk call for a separate diagnostic and
risk-based plan. The other options are less appropriate, unsafe, or inconsistent with the clinical
priority.
Q3: Situation: a healthy 52-year-old with no breast symptoms, prior breast cancer, or
high-risk mutation asks when her next screening mammogram is due. For average-risk
breast cancer screening, which evidence-based principle applies?
A. Recommend screening mammography every 2 years through age 74, with individualized care
if her risk or health status changes [CORRECT]
B. Order screening MRI instead of mammography for all average-risk patients
C. Recommend annual mammography for every patient regardless of risk
D. Stop screening at age 50
Correct Answer: A
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk call for a separate diagnostic and
risk-based plan. The other options are less appropriate, unsafe, or inconsistent with the clinical
priority.
Page 3 of 37
, Q4: A patient presents with the following history: a healthy 52-year-old with no breast
symptoms, prior breast cancer, or high-risk mutation asks when her next screening
mammogram is due. Which action is most appropriate?
A. Defer screening until a breast lump develops
B. Recommend annual mammography for every patient regardless of risk
C. Stop screening at age 50
D. Recommend screening mammography every 2 years through age 74, with individualized care
if her risk or health status changes [CORRECT]
Correct Answer: D
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk call for a separate diagnostic and
risk-based plan. The other options are less appropriate, unsafe, or inconsistent with the clinical
priority.
Q5: Priority situation: a healthy 52-year-old with no breast symptoms, prior breast cancer,
or high-risk mutation asks when her next screening mammogram is due. Which action
addresses the highest-risk issue?
A. Recommend annual mammography for every patient regardless of risk
B. Recommend screening mammography every 2 years through age 74, with individualized care
if her risk or health status changes [CORRECT]
C. Order screening MRI instead of mammography for all average-risk patients
D. Defer screening until a breast lump develops
Correct Answer: B
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk call for a separate diagnostic and
risk-based plan. The other options are less appropriate, unsafe, or inconsistent with the clinical
priority.
Q6: Which recommendation is appropriate for cervical cancer screening interval?
A. Perform cervical screening at every visit regardless of the last result
B. Order HPV cotesting every year for all patients under 30
C. Stop screening because she received HPV vaccination
D. Explain that routine cytology is due at a 3-year interval for average-risk patients ages 21–29,
so she is not yet due [CORRECT]
Correct Answer: D
Rationale: For average-risk patients ages 21–29, the 2018 USPSTF guidance in effect in
2024 recommends cytology every 3 years; vaccination does not eliminate routine screening.
The other options are less appropriate, unsafe, or inconsistent with the clinical priority.
Page 4 of 37
